(Press-News.org) The global burden of dengue infection is more than triple current estimates from the World Health Organization, according to a multinational study published today in the journal 'Nature'.
The research has created the first detailed and up-to-date map of dengue distribution worldwide, enabling researchers to estimate the total numbers of people affected by the virus globally, regionally and nationally. The findings will help to guide efforts in vaccine, drug and vector control strategies.
The study was led by Professor Simon Hay, a Wellcome Trust Senior Research Fellow at the University of Oxford, as part of the International Research Consortium on Dengue Risk Assessment, Management and Surveillance.
Dengue, also known as 'breakbone fever', is a viral infection that is transmitted between humans by mosquitoes. In some people, it causes life-threatening illness.
There are currently no licensed vaccines or specific treatments for dengue, and substantial efforts to control the mosquitoes that transmit the disease have not stopped its rapid emergence and global spread. Until now, little was known about the current distribution of the risk of dengue virus infection and its public health burden around the world.
Dr Samir Bhatt, who led the modelling for the study, says: "Our aim was to take all of the evidence that is currently available on the distribution of dengue worldwide and combine it with the latest in mapping and mathematical modelling to produce the most refined risk maps and burden estimates. We then hope to use this knowledge to help predict the future burden of the disease."
The findings reveal that dengue is ubiquitous throughout the tropics, with local spatial variations in risk influenced strongly by rainfall, temperature and urbanisation. The team estimate that there are 390 million dengue infections across the globe each year, of which 96 million reach any level of clinical or subclinical severity. This is more than triple the WHO's most recent estimates of 50-100 million infections per year.
Professor Simon Hay explains: "We found that climate and population spread were important factors for predicting the current risk of dengue around the world. With globalisation and the constant march of urbanisation, we anticipate that there could be dramatic shifts in the distribution of the disease in the future: the virus may be introduced to areas that previously were not at risk, and those that are currently affected may experience increases in the number of infections.
"We hope that the research will initiate a wider discussion about the significant global impact of this disease."
Of the 96 million apparent infections, Asia bore 70 per cent of the burden. India alone accounted for around one-third of all infections. The results indicate that with 16 million infections, Africa's burden is almost equivalent to that of the Americas and is significantly larger than previously appreciated. The authors suggest that the hidden African dengue burden could be a result of the disease being masked by symptomatically similar illnesses, under-reporting and highly variable treatment-seeking behaviour.
Professor Jeremy Farrar, Director of the Wellcome Trust Vietnam Research Programme and Oxford University Clinical Research Unit Hospital for Tropical Diseases in Vietnam, explains that the map and estimates produced by Hay's group set the benchmark for the disease: "This is the first systematic robust estimate of the extent of dengue. The evidence that we've gathered here will help to maximise the value and cost-effectiveness of public health and clinical efforts, by indicating where limited resources can be targeted for maximum possible impact
With endemic transmission in Asia and the Americas, recent outbreaks in Portugal, the ever-increasing incidence in Africa, and the challenges of making an effective dengue vaccine or controlling the vector, Professor Farrar stresses: "This really does represent a crucial period in the global spread of dengue."
Jimmy Whitworth, Head of International Activities at the Wellcome Trust, said: "Over time, this comprehensive map of global disease burden will also help to demonstrate which control measures are making the biggest difference in reducing the number of people suffering from dengue infection. Without a vaccine or specific treatment options, it's crucial that we understand where best to direct the limited resources available for preventing this resurgent disease."
###
The International Research Consortium on Dengue Risk Assessment, Management and Surveillance is a multinational team of researchers funded by the European Commission to develop new and innovative tools to be applied to the control of dengue in a global context. This study also received funding from the Wellcome Trust, the Department of Homeland Security, Li Ka Shing Foundation and the Fogarty International Center, National Institutes of Health.
The publication of the findings coincides with the first regional meeting of the World Health Summit in Singapore, where health care policy makers, experts, and practitioners are coming together to exchange ideas and find solutions for today's health challenges in Asia.
Global burden of dengue is triple current estimates
2013-04-08
ELSE PRESS RELEASES FROM THIS DATE:
Adhesive force differences enable separation of stem cells to advance therapies
2013-04-08
A new separation process that depends on an easily-distinguished physical difference in adhesive forces among cells could help expand production of stem cells generated through cell reprogramming. By facilitating new research, the separation process could also lead to improvements in the reprogramming technique itself and help scientists model certain disease processes.
The reprogramming technique allows a small percentage of cells – often taken from the skin or blood – to become human induced pluripotent stem cells (hiPSCs) capable of producing a wide range of other ...
Retinoic acid gradient visualized for the first time in an embryo
2013-04-08
In a ground-breaking study, researchers from the RIKEN Brain Science Institute in Japan report a new technique that allows them to visualize the distribution of retinoic acid in a live zebrafish embryo, in real-time. This technique enabled them to observe two concentration gradients going in opposing directions along the head-to-tail axis of the embryo, thus providing long-awaited evidence that retinoic acid is a morphogen.
The report, published today in the journal Nature, puts an end to a long-standing debate around the presence of retinoic acid gradients across the ...
Researchers shine light on how stress circuits learn
2013-04-08
Researchers at the University of Calgary's Hotchkiss Brain Institute have discovered that stress circuits in the brain undergo profound learning early in life. Using a number of cutting edge approaches, including optogenetics, Jaideep Bains, PhD, and colleagues have shown stress circuits are capable of self-tuning following a single stress. These findings demonstrate that the brain uses stress experience during early life to prepare and optimize for subsequent challenges.
The team was able to show the existence of unique time windows following brief stress challenges ...
Finding genes for childhood obesity
2013-04-08
Researchers have identified four genes newly associated with severe childhood obesity. They also found an increased burden of rare structural variations in severely obese children.
The team found that structural variations can delete sections of DNA that help to maintain protein receptors known to be involved in the regulation of weight. These receptors are promising targets for the development of new drugs against obesity.
As one of the major health issues affecting modern societies, obesity has increasingly received public attention. Genes, behavior and environment, ...
Final chapter to 60-year-old blood group mystery
2013-04-08
Researchers have uncovered the gene at the root of a human blood group that has remained a mystery for the past 60 years. They showed that a genetic deletion on this gene is responsible for the lack of this blood group in some people.
With the discovery of the gene behind the Vel blood group, medical scientists can now develop a more reliable DNA test to identify people who lack this group. This will reduce the risk of severe, and sometimes life threatening, destruction of the Vel-positive donor red blood cells in patients with antibodies against Vel.
The genetic basis ...
Low levels of serum bilirubin spell higher lung cancer risk for male smokers
2013-04-08
WASHINGTON, D.C. – Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the yellow-tinged chemical are at higher risk for lung cancer and dying from the disease.
A team led by researchers at The University of Texas MD Anderson Cancer Center reported its findings in a late-breaking abstract at the AACR Annual Meeting 2013 in Washington, D.C.
"Our study indicates male smokers with low levels of bilirubin are a high-risk ...
Cleveland Clinic researchers discover new link between heart disease and red meat
2013-04-08
EMBARGOED UNTIL 1 P.M. EDT, APRIL 7, 2013, Cleveland: A compound abundant in red meat and added as a supplement to popular energy drinks has been found to promote atherosclerosis – or the hardening or clogging of the arteries – according to Cleveland Clinic research published online this week in the journal Nature Medicine.
The study shows that bacteria living in the human digestive tract metabolize the compound carnitine, turning it into trimethylamine-N-oxide (TMAO), a metabolite the researchers previously linked in a 2011 study to the promotion of atherosclerosis ...
Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
2013-04-08
WASHINGTON–A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.
The findings (abstract LB-202) will be released at a press conference on Sunday, April 7, 2 p.m. ET, and later at an oral presentation on Tuesday, April 9, 2 p.m. ET, in Room 153, in the Washington Convention Center.
The two oral drugs, sapacitabine and seliciclib, ...
Arrhythmia drug may increase cancer risk
2013-04-08
One of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug. That is the conclusion of a new retrospective study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results indicate that a potential link between amiodarone and cancer warrants further investigation.
Amiodarone was approved in 1985 for the treatment of arrhythmias, or irregular heartbeats. Because the drug is fat-soluble and degrades very slowly, ...
Developmental delays in children following prolonged seizures
2013-04-08
Researchers from the UK determined that developmental delays are present in children within six weeks following convulsive status epilepticus (CSE)—a seizure lasting longer than thirty minutes. The study appearing today in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), suggests that neurodevelopmental impairments continue to be present one year after CSE.
CSE is one of the most common neurological emergencies in children. These prolonged seizures can occur with or without fevers (febrile). Studies show that CSE ...